PET-CT with the radioactive tracer 18F-NaF PET-CT helps clinicians detect ruptured and high-risk coronary plaques.
Images from 18F-NaF PET-CT allow clinicians to identify and localize ruptured and high-risk coronary plaque, according to a study published in The Lancet.
Researchers from the United Kingdom undertook a prospective clinical trial to determine if using PET and CT with radioactive tracers could help clinicians in the prevention and treatment of coronary heart disease.
Forty patients who had experienced a myocardial infarction (MI) and 40 who had stable angina were enrolled into the study. All underwent 18F-sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) PET-CT and invasive coronary angiography. The researchers compared 18F-FDG with histology in carotid endarterectomy specimens from patients with symptomatic carotid disease and with intravascular ultrasound in patients with stable angina.
In 37 patients (93 percent) with MI, the highest coronary uptake of radioactive tracer 18F-NaF was in ruptured (culprit) plaques (culprit 1·66 [IQR 1·40-2·25]) compared to un-ruptured, but high-risk, (non-culprit) plaques (1·66 [IQR 1·40-2·25]). A similar difference between culprit and non-culprit plaques wasn’t seen when researchers used the current, standard noninvasive tracer 18F-FDG (1·71 [1·40-2·13] vs 1·58 [1·28-2·01], p=0·34). Marked 18F-NaF uptake occurred with all carotid plaque ruptures and was associated with active calcification, macrophage infiltration, apoptosis, and necrosis.
Of those patients with stable angina, 45 percent (18 patients) had increased 18F-NaF uptake (maximum tissue-to-background ratio 1·90 [IQR 1·61-2·17]) associated with more high-risk features on intravascular ultrasound than plaques without tracer uptake, such as positive remodeling, microcalcification, and necrotic core.
The authors concluded 18F-NaF PET-CT is the first non-invasive imaging method to identify and localize ruptured and high-risk coronary plaque. They pointed out, however, that more study is needed to see if this is a feasible method to improve coronary artery disease care.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.